Advancing a New Maternal-Fetal Treatment for Early-Onset Preeclampsia

Sébastien Mazzuri of the EspeRare Foundation in Switzerland and its partners will reposition an oral drug previously evaluated in cardiovascular patients as a treatment candidate for early-onset preeclampsia. The drug has an extensive data package and advanced to Phase 3 trials before discontinuation for lack of superiority over standard of care. Leveraging preliminary research suggesting it could beneficially rebalance key physiological disruptions underlying preeclampsia, EspeRare will drive translational proof-of-concept studies in established preclinical models and coordinate advisory board consultations to guide the clinical trial design. The goal is to confirm the drug's therapeutic potential in preeclampsia and accelerate regulatory clearance for clinical evaluation. Ultimately this new therapeutic approach aims to significantly improve survival and health outcomes for pregnant women and their unborn children, with a focus on accessibility in high-burden regions.